Impact of the COVID-19 Pandemic on the Surgical Activity of Bellvitge University Hospital
- Conditions
- Nosocomial InfectionCovid19Surgery--Complications
- Interventions
- Procedure: The study evaluates all surgical patients operated, both elective scheduled and emergent cases
- Registration Number
- NCT04780594
- Lead Sponsor
- Hospital Universitari de Bellvitge
- Brief Summary
COVID-19 has been a challenge for hospitals; there was an obvious need to reconvert many spaces in specific areas to attend this pathology, without forgetting the attention to other pathologies and surgery. The objective of the investigators is to evaluate the impact of this pandemic in the patients who underwent surgery in Bellvitge University Hospital, analyzing 2 periods of time: the months before the COVID-19 peak and the COVID-19 peak months.
- Detailed Description
A total of 2.530 procedures have been evaluated in this retrospective observational study. Two groups have been generated (pre-pandemic period and pandemic period), classified into scheduled and emergency surgery. The investigators determined age, type of surgery and specialty, hospital stay, destination at discharge including mortality and severity according to Diagnostic Related to Group (DRG) scale. The investigators have also determined the number of confirmed COVID-19 infections in patients who underwent surgery during these 2 periods and evaluated if the infection was due to a nosocomial infection (confirmation of the COVID-19 during the hospitalization period). Comparisons were made between subgroups: scheduled surgery performed during the 2 periods and emergency surgery performed during the 2 periods.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2530
- All surgical patients operated, both elective scheduled and emergent cases
- Minor-intermediate surgery that involves discharge from the hospital on the same day of the surgery from the Pre-pandemic period.
- Procedures related to medical treatment or complications of COVID-19 patients, such as chest tubes, extracorporeal oxygenation or tracheostomy.
- Those scheduled elective surgery patients in the Covid period that resulted RT-PCR positive, surgery was posponed, were not considered eligible for the analysis.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Pandemic COVID-19 group (COVID) The study evaluates all surgical patients operated, both elective scheduled and emergent cases All patients who underwent surgery from 11th March 2020 until 15th May 2020, which were done during the first wave of the pandemic crisis. Pre-pandemic COVID-19 group (PreCOVID) The study evaluates all surgical patients operated, both elective scheduled and emergent cases All patients who underwent surgery from 13th January until 29th February 2020, which are considered free of COVID-19 patients, therefore pre-pandemic period.
- Primary Outcome Measures
Name Time Method Register the post-surgical complications PreCOVID group from 13th January 2020 to 29th February 2020 and COVID group from 11th March 2020 to 15th May 2020. Register and Compare the Rate of Surgical Reintervention between both periods.
- Secondary Outcome Measures
Name Time Method Register the rate of surgical reintervention PreCOVID group from 13th January 2020 to 29th February 2020 and COVID group from 11th March 2020 to 15th May 2020. Register and compare the Rate of reintervention between both periods.
Register the ICU admission PreCOVID group from 13th January 2020 to 29th February 2020 and COVID group from 11th March 2020 to 15th May 2020. register and compare the ICU admission between both periods.
Register the Hospital stay PreCOVID group from 13th January 2020 to 29th February 2020 and COVID group from 11th March 2020 to 15th May 2020. register and compare the ICU admission between both periods.
Register the Mortality PreCOVID group from 13th January 2020 to 29th February 2020 and COVID group from 11th March 2020 to 15th May 2020. register and compare the Mortality between both periods.
Trial Locations
- Locations (1)
Marta Caballero
🇪🇸Hospitalet de Llobregat, Barcelona, Spain